P & G Health Ltd (PGHL)

FairStock Score: 38/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• Extraordinary capital efficiency: ROE of 52.95% and ROCE of 47.75% indicate a strong franchise.
• Balance sheet is virtually debt-free with Debt/Equity of 0.01, reducing financial risk.
• Sales growth of 20.69% shows healthy revenue momentum, with latest quarter sales at ₹374 Cr.
• Promoter holding of 51.82% aligns management interests with minority shareholders.
• Dividend yield of 2.55% provides some cash return while waiting for valuation to cool.

Concerns

• Profit declined 14.64% despite 20.69% sales growth, indicating significant margin compression.
• Valuation is demanding: P/E of 27.72 and P/B of 14.15 versus book value of ₹367.86 leave little margin of safety.
• Piotroski F-Score of 4/9 suggests deteriorating financial health and operational quality.
• Recent share price remains meaningfully below the 52-week high of ₹6975, reflecting earnings disappointment.

AI Analysis

At heart of my approach is simple: a great business is only a great investment at the right price. P&G Health Ltd posts numbers that would make any capitalist smile. It earns 52.95% on equity and 47.75% on capital employed, with debt-to-equity of just 0.01. That tells me it has pricing power and does not need leverage to grow. Promoters holding 51.82% is also reassuring. But Graham insisted on margin of safety, and at ₹5205.90 the stock offers little. P/E of 27.72 and price-to-book of 14.15 against book value of ₹367.86 means I am mostly paying for future optimism. Sales grew 20.69% in the last year, yet profit fell 14.64%. In other words, the company is making more rupees in revenue but fewer in earnings. The latest quarter shows ₹374 Cr sales and ₹78 Cr net profit, but one quarter does not reverse a negative trend. Piotroski F-Score of 4/9 is a warning; the underlying financial health is mixed. A 2.55% dividend yield is nice, but it does not justify an entry price where any stumble in earnings could hit the share price hard. The 52-week high is ₹6975; the stock has already corrected, but cheapness is not measured from the high. FairStock Score 46/100 calls it mixed, and I agree. This is a high-quality franchise, possibly a stalwart consumer health business, but I would need lower valuation or concrete proof that profit margins have stabilized before acting. For now, I will watch and wait.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer